类风湿关节炎患者接受阿巴西普与其他改善病情抗风湿药治疗的恶性肿瘤结局:一项10年国际上市后研究结果
该国际上市后观察性安全性研究纳入ARTIS、RABBIT、FORWARD和BC四个数据源,评估阿巴西普(n=5182)、传统合成DMARDs(n=73755)和其他生物/靶向合成DMARDs(n=37195)治疗类风湿关节炎患者的恶性肿瘤风险,汇总分析未发现阿巴西普较对照组总体恶性肿瘤风险有统计学显著增加。
要点
- 阿巴西普组总体恶性肿瘤汇总率比(RR)对比csDMARDs为1.1(95%CI 0.8-1.5),对比其他b/tsDMARDs为1.0(95%CI 0.8-1.3)。
- ARTIS登记处观察到阿巴西普对比csDMARDs的淋巴瘤RR为2.8(95%CI 1.1-6.8)。
- 部分登记处乳腺癌、肺癌和淋巴瘤个体癌症例数低,RR无法获得。
核心结论
- 该国际上市后观察性安全性研究的汇总数据未发现阿巴西普治疗患者较csDMARDs或其他b/tsDMARDs治疗患者总体恶性肿瘤风险有统计学显著增加。
- 需要评估更大规模人群以进一步评价个体癌症(尤其是淋巴瘤)的风险。
研究设计与样本
- 国际观察性上市后安全性研究,纳入四个国际观察性数据源:ARTIS(瑞典)、RABBIT(德国)、FORWARD(美国)和BC(加拿大)。
- 阿巴西普组n=5182,平均随访3.0-3.7年;csDMARDs组n=73755,平均随访2.9-6.2年;其他b/tsDMARDs组n=37195,平均随访3.1-4.7年。
- 计算每1000患者年暴露的粗发病率(IR)及95%CI,估计率比(RR)并调整人口学特征、合并症和其他潜在混杂因素,RR采用随机效应模型汇总。
主要发现
- 总体恶性肿瘤每1000患者年IR范围:阿巴西普组7.6-11.4,csDMARDs组8.6-13.2,其他b/tsDMARDs组5.0-11.8。
- 乳腺癌每1000患者年IR范围:阿巴西普组0-4.4,csDMARDs组0-3.3,其他b/tsDMARDs组0-2.5。
- 肺癌每1000患者年IR范围:阿巴西普组0.1-2.8,csDMARDs组0-3.7,其他b/tsDMARDs组0.2-2.9。
- 淋巴瘤每1000患者年IR范围:阿巴西普组0-1.1,csDMARDs组0-0.9,其他b/tsDMARDs组0-0.6。
- ARTIS登记处观察到阿巴西普对比csDMARDs的淋巴瘤RR为2.8(95%CI 1.1-6.8)。
关键数值与推荐
- 部分登记处乳腺癌、肺癌和淋巴瘤的个体癌症例数低,RR无法获得。
- 阿巴西普组总体恶性肿瘤汇总RR对比csDMARDs为1.1(95%CI 0.8-1.5),对比其他b/tsDMARDs为1.0(95%CI 0.8-1.3)。
- ARTIS登记处阿巴西普对比csDMARDs的淋巴瘤RR为2.8(95%CI 1.1-6.8)。
临床怎么用
- 该研究为上市后观察性安全性研究,原文结论未据此给出具体临床推荐。
局限性
- 部分登记处乳腺癌、肺癌和淋巴瘤的个体癌症例数低,RR无法获得。
- 部分登记处淋巴瘤例数少;ARTIS观察到阿巴西普对比csDMARDs的淋巴瘤RR为2.8(95%CI 1.1-6.8)。
- 需要评估更大规模人群以进一步评价个体癌症(尤其是淋巴瘤)的风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the risk of malignancy (overall, breast, lung, and lymphoma) in patients with rheumatoid arthritis treated with abatacept, conventional synthetic (cs) disease-modifying antirheumatic drugs (DMARDs), and other biologic/targeted synthetic (b/ts)DMARDs in clinical practice. METHODS: Four international observational data sources were included: ARTIS (Sweden), RABBIT (Germany), FORWARD (USA), and BC (Canada). Crude incidence rates (IRs) per 1000 patient-years of exposure with 95% confidence intervals (CIs) for a malignancy event were calculated; rate ratios (RRs) were estimated and adjusted for demographics, comorbidities, and other potential confounders. RRs were then pooled in a random-effects model. RESULTS: Across data sources, mean follow-up for patients treated with abatacept (n = 5182), csDMARDs (n = 73,755), and other b/tsDMARDs (n = 37,195) was 3.0-3.7, 2.9-6.2, and 3.1-4.7 years, respectively. IRs per 1000 patient-years for overall malignancy ranged from 7.6-11.4 (abatacept), 8.6-13.2 (csDMARDs), and 5.0-11.8 (other b/tsDMARDs). IRs ranged from: 0-4.4, 0-3.3, and 0-2.5 (breast cancer); 0.1-2.8, 0-3.7, and 0.2-2.9 (lung cancer); and 0-1.1, 0-0.9, and 0-0.6 (lymphoma), respectively, for the three treatment groups. The numbers of individual cancers (breast, lung, and lymphoma) in some registries were low; RRs were not available. There were a few cases of lymphoma in some of the registries; ARTIS observed an RR of 2.8 (95% CI 1.1-6.8) with abatacept versus csDMARDs. The pooled RRs (95% CIs) for overall malignancy with abatacept were 1.1 (0.8-1.5) versus csDMARDs and 1.0 (0.8-1.3) versus b/tsDMARDs. CONCLUSIONS: This international, post-marketing observational safety study did not find any statistically significant increase in the risk of overall malignancies in pooled data in patients treated with abatacept compared with csDMARDs or with other b/tsDMARDs. Assessment of larger populations is needed to further evaluate the risks for individual cancers, especially lymphoma.
引用
- Simon TA, Suissa S, Boers M, et al. Malignancy outcomes in patients with rheumatoid arthritis treated with abatacept and other disease-modifying antirheumatic drugs: Results from a 10-year international post-marketing study. Semin Arthritis Rheum. 2023. PMID: 37500379. doi:10.1016/j.semarthrit.2023.152240
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。